Evidence map›Paper›PMID 31442511›Full record

ReviewProgress in cardiovascular diseases

Cardiovascular outcome trials of the newer anti-diabetic medications.

Tushar Acharya, Prakash Deedwania

Abstract readReview
PubMed Publisher
In one paragraph

Review in Progress in cardiovascular diseases. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
3.7field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it, 30 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. [Prevention of ischemic stroke in old age].Zeitschrift fur Gerontologie und Geriatrie · 2024
    Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Can SGLT2 Inhibitor be Used for Diabetes Mellitus or Vascular Diseases?Journal of atherosclerosis and thrombosis · 2020
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Tushar AcharyaUniversity of Arizona College of Medicine, Tucson, United States of America. Electronic address: tacharya@shc.arizona.edu.
Prakash DeedwaniaUniversity of California, San Francisco, United States of America. Electronic address: pdeedwania@fresno.ucsf.edu.
University of Arizona · USUniversity of California, San Francisco · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Concerns of elevated cardiovascular disease (CVD) risk with some anti-diabetic medications warranted phase 4 clinical trials to demonstrate CVD safety of newly marketed anti-diabetic drugs. Although initially designed to evaluate safety, some of these CVD outcome trials (CVOTs) have in fact shown CVD benefits. New medication classes, like glucagon-like peptide 1 (GLP-1) analogues and sodium-glucose co-transporter 2 (SGLT2) inhibitors, have shown reductions in the risk of major adverse cardiovascular events (MACE) including, myocardial infarction, stroke, CV death, and heart failure (HF). Perhaps more importantly, SGLT2 inhibitors demonstrated reduction in the risk of HF hospitalizations, being the first class of anti-diabetic drugs to do so. Conversely, dipeptidyl peptidase 4 (DPP-4) inhibitors did not significantly affect atherosclerotic CVD end-points and some actually increased the risk of HF hospitalizations. Further, the adverse/beneficial CVD effects of these medications may not be class specific. This review focuses on the main results of these CVOTs while highlighting the heterogeneity of CVD end-points within each class and discusses important mechanistic insights and adverse effect profiles.

Indexed as

AgedCardiovascular DiseasesCardiovascular SystemClinical Trials, Phase IV as TopicDiabetes Mellitus, Type 2Dipeptidyl-Peptidase IV InhibitorsFemaleFollow-Up StudiesGlucagon-Like Peptide 1HumansHypoglycemic AgentsIncidenceMaleMiddle AgedPatient SafetyRisk AssessmentDipeptidyl-Peptidase IV InhibitorsGlucagon-Like Peptide 1Hypoglycemic AgentsSodium-Glucose Transporter 2 InhibitorsCardiovascular diseaseDiabetes mellitusGLP-1 analoguesMedicationsSGLT2 inhibitors

Identifiers

PMID31442511
OpenAlexW2969797069

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.